Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLM2010 Comparative Pharmacokinetic Study
NCT07817004Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Nov 2026
01
Overview
Phase 1, randomised, open-label trial of aprepitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area Under the Curve at 10 weeks and Peak Plasma Concentration at 10 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
aprepitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07817004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817004.